Mr. O'Connor will be compensated according to the Company's Non-Employee Director Compensation Policy and Non-Employee Director Stock Option Grant Policy and will also be entitled to indemnification pursuant to the standard indemnification agreement between the Company and its officers and directors.

Under the Company's Non-Employee Director Compensation Policy, each eligible director is paid an annual retainer of $10,000 for membership on the Board and additional annual retainers of $5,000 for serving as Chairman of the Compensation Committee or the Chairman of the Nominati ng and Corporate Governance Committee, $15,000 for serving as Chairman of the Audit Committee, $1,000 for serving as a member of the Compensation Committee or a member of the Nominating and Corporate Governance Committee, and $2,500 for serving as member of the Audit Committee. All annual retainers are paid in quarterly installments, and are pro-rated for period of service if a director's service ends prematurely. Each eligible director is also paid $2,500 for each regularly scheduled quarterly meeting of the Board attended in person, $1,000 for each regularly scheduled quarterly meeting of the Board attended via telephone or videoconferencing, $500 for each special meeting of the Board attended in person or via telephone or videoconferencing, and $500 for each committee meeting of the Board attended in person or via telephone or videoconferencing. Regardless of the foregoing, no eligible director may receive more than $40,000 in any calendar year without specific approval of the Board. All members of th e Board receive reimbursement of travel and other expenses reasonably incurred in connection with attending meetings of the Board or committees thereof. As Chair of the Audit Committee, Mr. O'Connor will be entitled to an annual retainer of $25,000 for his service, fees for attendance at meetings as set forth above, and travel reimbursement.

Under the Company's Non-Employee Director Stock Option Grant Policy, each eligible director is granted a non-statutory stock option to purchase 20,000 shares of the Company's common stock (subject to adjustment in accordance with the Company's 2006 Stock Option and Incentive Plan) upon his or her initial election or appointment to the Board. Each such director is also granted a non-statutory option to purchase 7,500 shares of the Company's common stock (again subject to adjustment in accordance with the Company's 2006 Stock Option and Incentive Plan) at the first meeting of the Board following each annual meeting of the Company's stockholders, provided that such dire ctor has served in that capacity for at least six months. All of the foregoing grants are made at the market value of the Company's common stock on the date of grant, vest in three equal annual installments on the anniversary of the grant date, and terminate five years from the date of grant (or, if earlier, 90 days after the end of the grantee's service as a member of the Board).

The information contained in Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

Exhibit      Description

LeMaitre Vascular, Inc. (Nasdaq: LMAT) today announced that John J. O'Connor has been appointed to its Board of Directors. Prior to his retirement in 2006, O'Connor was vice chairman of services for PricewaterhouseCoopers LLP (PwC) and served as partner at the firm for 24 years. Mr. O'Connor will serve as a Class III director, standing for election at the next annual meeting of the company's shareholders, and will also serve as Chair of the company's Audit Committee.

"We are delighted to welcome someone of John's stature and talent to our Board," said George W. LeMaitre, Chairman and CEO, who added "John's financial and strategic acumen is an ideal complement to the skills of our other Board members."

As vice chairman of services at PwC, O'Connor was responsible for the firm's audit, tax and advisory lines of service, which at the time had combined revenue of approximately $7 billion and employed approximately 28,000 people. In addition to providing leadership to the lines of service, he was responsible for marketing, finance and operations. O'Connor also oversaw the firm's Center for Advanced Research and led the development of the Future of PwC, a long term strategy initiative to explore the economic, global and demographic trends that impact PwC clients and business. O'Connor previously served as the leader of the U.S. audit practice, and before that as the managing partner of the firm's Boston office. He is a graduate of Suffolk University and has attended the Harvard Business School's Leadership in Professional Service Firms program and the executive M.B.A. program at the Amos Tuck School at Dartmouth College.

LeMaitre Vascular expects that the appointment of Mr. O'Connor to its Board of Directors and Audit Committee will cause it to regain compliance with the Marketplace Rules of The Nasdaq Stock Market, which require that a majority of the Company's Board of Directors be independent and that the Company's Audit Committee be composed of three or more independent directors. The appointment of Mr. O'Connor falls within Nasdaq's permitted cure period for such matters.

About LeMaitre Vascular

LeMaitre Vascular develops, manufactures, and markets medical devices for the treatment of peripheral vascular disease. The company's principal executive offices are located at 63 Second Avenue, Burlington, Massachusetts 01803.

Certain statements set forth above that are not clearly historical in nature are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, the Company's anticipation that it will regain compliance with Nasdaq Marketplace Rules. Although the Company believes that such statements are based on reasonable assumptions within the bounds of its knowledge, these forward-looking statements are neither promises nor guarantees. The forward-looking statements made in this release are made only as of the date hereof, and the Company disclaims any intention or responsibility for updating predictions or expectations contained in this release.

CONTACT:
Aaron Grossman
Office: 781.221.2266
Investor Relations
LeMaitre Vascular, Inc.

SOURCE:
LeMaitre Vascular, Inc.